Abstract
In vitro models are essential to understanding the molecular characteristics of colorectal cancer (CRC) and the testing of therapies for CRC. Many efforts to establish and characterize primary CRC cell lines have been published, most describing a small number of novel cell lines. However, there remains a lack of a large panel of uniformly established and characterized cell lines. To this end we established 20 novel CRC cell lines, of which six were derived from liver metastases. Genetic, genomic and transcriptomic profiling was performed in order to characterize these new cell lines. All data are made publically available upon publication.By combining mutation profiles with CNA and gene expression profiles, we generated an overall profile of the alterations in the major CRC-related signaling pathways. The combination of mutation profiles with genome, transcriptome and methylome data means that these low passage cell lines are among the best characterized of all CRC cell lines. This will allow researchers to select model cell lines appropriate to specific experiments, facilitating the optimal use of these cell lines as in vitro models for CRC. All cell lines are available for further research.
Highlights
With over a million cases diagnosed every year, colorectal cancer (CRC) is the third most commonly occurring cancer in the world (Globocan 2012)
Metastatic CRC is often treated using the FOLFOX protocol, a series of chemotherapy treatments consisting of oxaliplatin and 5-FU. mCRC without RAS mutations are treated with EGFR inhibition therapies such as cetuximab and panitumumab
We report the establishment of 20 novel CRC cell lines, 14 of which were derived from primary colorectal cancers, while the remaining 6 were established from liver metastases
Summary
With over a million cases diagnosed every year, colorectal cancer (CRC) is the third most commonly occurring cancer in the world (Globocan 2012). The occurrence of metastatic disease has a major impact on patient survival: CRC patients presenting with distant metastases have a 5-year survival rate of only 12%, while patients with local disease or regional spreading of disease show 5-year survival rates of 90% and 70%, respectively [1]. One third of CRC cases already show distant metastases at diagnosis and around 50-60% of these metastases are found in the liver [2,3,4]. Metastatic CRC (mCRC) is often treated using the FOLFOX protocol, a series of chemotherapy treatments consisting of oxaliplatin and 5-FU. MCRC without RAS mutations are treated with EGFR inhibition therapies such as cetuximab and panitumumab. Patients without RAS mutations show a median overall survival of 23.8 months on this treatment [5]. Patients with RAS mutant CRC are ineligible for EGFR inhibition therapy and show a median overall survival of 19.2 months
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
